CRSP · XBRL financial data

CRISPR Therapeutics financial statements, every fiscal year

The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (CRSP's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue from contracts with customers	1	915	1	371	37	4
Research and development	267	439	462	387	321	285
General and administrative	88	103	102	76	73	74
Total operating expenses	355	541	674	594	504	668
Operating income (loss)	(354)	374	(673)	(223)	(467)	(665)
Interest income	—	—	23	76	104	—
Other income (expense)	6	6	23	72	104	87
Income tax expense (benefit)	1	2	(0)	3	4	4
Net income (loss)	(349)	378	(650)	(154)	(366)	(582)
Earnings per share, basic USD per share	(5.29)	4.97	(8.36)	(1.94)	(4.34)	(6.47)
Earnings per share, diluted USD per share	(5.29)	4.70	(8.36)	(1.94)	(4.34)	(6.47)
Weighted average shares, basic millions of shares	66	76	78	79	84	90
Weighted average shares, diluted millions of shares	66	80	78	79	84	90

Fiscal years (CRSP's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	1,169	923	212	389	298	348
Marketable securities	522	1,456	1,603	1,304	1,606	1,628
Marketable securities, non-current	—	0	53	2	0	0
Accounts receivable	0	0	0	200	25	0
Prepaid and other current assets	26	38	38	14	8	10
Total current assets	1,717	2,418	1,853	1,908	1,937	1,986
Property and equipment, net	42	138	164	152	134	116
Right-of-use asset	51	174	157	154	143	132
Total assets	1,828	2,752	2,243	2,230	2,242	2,265
Accounts payable	9	15	27	38	15	11
Accrued liabilities	54	91	78	45	41	89
Total current liabilities	94	120	121	109	88	149
Lease liability, non-current	50	213	228	223	206	188
Total liabilities	164	352	368	347	310	343
Accumulated deficit	(574)	(196)	(846)	(1,000)	(1,366)	(1,948)
Total stockholders' equity	1,664	2,399	1,875	1,883	1,932	1,922
Total liabilities and equity	1,828	2,752	2,243	2,230	2,242	2,265
Common shares outstanding (cover page) millions of shares	75	77	79	80	86	96

Fiscal years (CRSP's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(349)	378	(650)	(154)	(366)	(582)
Stock-based compensation	66	102	98	81	87	72
Depreciation and amortization	9	18	24	20	19	19
Net cash from operating activities	(238)	539	(496)	(260)	(143)	(345)
Purchases of property and equipment	18	82	37	9	2	1
Net cash from investing activities	(541)	(1,035)	(259)	375	(280)	(32)
Proceeds from issuing common stock	982	213	1	33	301	398
Net cash from financing activities	1,016	251	39	63	332	426
Net change in cash	237	(246)	(716)	177	(91)	49

SIC 2836 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2836 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($M)	Revenue, quarter ($M)	Operating cash flow, quarter ($M)	Shares outstanding	Runway	Quarter
CRISPR Therapeutics	192	13	(90)*	97.0M	24.0 quarters	Q3 FY26 10-QSep 30, 2026
Soleno Therapeutics	133	not reported	26	52.1M	—	Q1 FY26 10-QMar 31, 2026
Adma Biologics	125	141	17*	221.9M	—	Q3 FY26 10-QSep 30, 2026
Lantheus Holdings	593	388	92*	65.3M	—	Q2 FY26 10-QJun 30, 2026
Merus	367	12	(85)*	75.8M	7.5 quarters	Q3 FY25 10-QSep 30, 2025
Axsome Therapeutics	314	260	(9.5)*	52.6M	14.7 quarters	Q3 FY26 10-QSep 30, 2026
Rhythm Pharmaceuticals	40	92	(3.1)*	69.3M	16.9 quarters	Q3 FY26 10-QSep 30, 2026
Halozyme Therapeutics	163	481	241*	113.5M	—	Q2 FY26 10-QJun 30, 2026
Vaxcyte	125	not reported	(224)*	158.3M	5.2 quarters	Q3 FY26 10-QSep 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.